Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Akero Therapeutics

DB:0K4
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0K4
DB
$599M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Akero Therapeutics has significant price volatility in the past 3 months.
0K4 Share Price and Events
7 Day Returns
4%
DB:0K4
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:0K4
-7.4%
DE Biotechs
-14.2%
DE Market
0K4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Akero Therapeutics (0K4) 4% -4.7% 1.1% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 0K4.
  • No trading data on 0K4.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Akero Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Akero Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €18.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Akero Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Akero Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0K4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.90
NasdaqGS:AKRO Share Price ** NasdaqGS (2020-04-08) in USD $20.96
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Akero Therapeutics.

DB:0K4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AKRO Share Price ÷ EPS (both in USD)

= 20.96 ÷ -2.90

-7.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akero Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Akero Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Akero Therapeutics's expected growth come at a high price?
Raw Data
DB:0K4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-18%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Akero Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Akero Therapeutics's assets?
Raw Data
DB:0K4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.54
NasdaqGS:AKRO Share Price * NasdaqGS (2020-04-08) in USD $20.96
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:0K4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AKRO Share Price ÷ Book Value per Share (both in USD)

= 20.96 ÷ 4.54

4.61x

* Primary Listing of Akero Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akero Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Akero Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Akero Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Akero Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-18%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Akero Therapeutics expected to grow at an attractive rate?
  • Unable to compare Akero Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Akero Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Akero Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0K4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0K4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -18%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0K4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0K4 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 0 -112 -124 4
2023-12-31 0 -98 -112 4
2022-12-31 0 -85 -95 6
2021-12-31 0 -68 -81 6
2020-12-31 0 -53 -66 6
2020-04-09
DB:0K4 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -44
2019-09-30 -26 -90
2019-06-30 -15 -86
2019-03-31 -10 -87
2018-12-31 -5 -82
2018-09-30 -4 -22
2017-12-31 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Akero Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Akero Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0K4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Akero Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0K4 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -3.34 -2.11 -4.78 4.00
2023-12-31 -3.29 -2.25 -4.71 4.00
2022-12-31 -2.88 -1.93 -4.87 6.00
2021-12-31 -2.66 -1.99 -4.60 6.00
2020-12-31 -2.37 -1.96 -3.26 6.00
2020-04-09
DB:0K4 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.90
2019-09-30 -11.25
2019-06-30 -91.75
2019-03-31 -644.16
2018-12-31 -795.24
2018-09-30 -95.36
2017-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Akero Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Akero Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Akero Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Akero Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Akero Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Akero Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Akero Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Akero Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Akero Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Akero Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0K4 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -43.76 8.61 37.05
2019-09-30 -89.82 6.52 25.88
2019-06-30 -85.66 4.57 13.25
2019-03-31 -87.18 3.16 15.71
2018-12-31 -82.23 1.91 11.87
2018-09-30 -21.59 1.19 10.58
2017-12-31 -5.21 1.18 3.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Akero Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Akero Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Akero Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Akero Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Akero Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Akero Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Akero Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Akero Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Akero Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Akero Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Akero Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Akero Therapeutics Company Filings, last reported 3 months ago.

DB:0K4 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 128.73 0.00 136.40
2019-09-30 143.38 0.00 147.84
2019-06-30 158.39 0.00 162.65
2019-03-31 69.66 0.00 69.80
2018-12-31 74.81 0.00 75.98
2018-09-30 4.77 0.00 7.83
2017-12-31 0.44 0.00 0.60
  • Akero Therapeutics has no debt.
  • Akero Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Akero Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Akero Therapeutics has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 81.1% each year.
X
Financial health checks
We assess Akero Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Akero Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Akero Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Akero Therapeutics dividends.
If you bought €2,000 of Akero Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Akero Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Akero Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0K4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0K4 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Akero Therapeutics has not reported any payouts.
  • Unable to verify if Akero Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Akero Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Akero Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Akero Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Akero Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Akero Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Akero Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andrew Cheng
COMPENSATION $1,345,555
AGE 52
TENURE AS CEO 1.6 years
CEO Bio

Dr. Andrew Cheng, MD, PhD, serves as Director of Arbutus Biopharma Corporation since August 17, 2019. He served as Chief Medical Officer & Executive Vice President of Gilead Sciences, Inc., since March 2018 until September 7, 2018. Dr. Cheng serves as the President and Chief Executive Officer at Akero Therapeutics Inc. since September 10, 2018 and serves as its Director. Dr. Cheng served as an Executive Vice President of Clinical Research & Development Operations at Gilead Sciences Inc. since January 2015 until March 2018. Dr. Cheng served as an Executive Vice President of HIV Therapeutics and Development Operations at Gilead Sciences Inc. since January 28, 2015. Dr. Cheng served as Senior Vice President of HIV Therapeutics at Gilead Sciences, Inc. until January 28, 2015. He is responsible for leading the company’s Medical Affairs organization, as well as overseeing clinical development for the company’s programs in HIV/AIDS. Dr. Cheng served as Senior Vice President of Development Operations at Gilead Sciences Inc., since January 2009 until March 2018. Dr. Cheng is responsible for Gilead's biometrics, clinical operations, drug safety and public health, project and portfolio management and regulatory affairs activities. He joined Gilead in 1999 and served as Vice President, Clinical Research, overseeing clinical development activities for Gilead's development-stage programs in HIV/AIDS. He has been Director of Global Virus Network since January 2013. He has been Director of Syntimmune, Inc. since April 2018. Prior to joining Gilead, he trained in internal medicine at the University of California, Los Angeles. Dr. Cheng received his Medical Degree and PhD in Cellular and Molecular Biology from Columbia University College of Physicians and Surgeons and holds a B.A. in biology from the Johns Hopkins University.

CEO Compensation
  • Insufficient data for Andrew to compare compensation growth.
  • Andrew's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Akero Therapeutics management team in years:

1.5
Average Tenure
50.5
Average Age
  • The average tenure for the Akero Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Andrew Cheng

TITLE
President
COMPENSATION
$1M
AGE
52
TENURE
1.6 yrs

Jonathan Young

TITLE
Co-Founder
COMPENSATION
$660K
AGE
49
TENURE
1.6 yrs

Tim Rolph

TITLE
Co-Founder & Chief Scientific Officer
COMPENSATION
$660K
AGE
65

Kitty Yale

TITLE
Executive VP & Chief Development Officer
COMPENSATION
$610K
AGE
47
TENURE
1.5 yrs

Bill White

TITLE
EVP, CFO & Head of Corporate Development
AGE
46
TENURE
1 yrs

John Schembri

TITLE
VP of Finance & Controller
AGE
57
Board of Directors Tenure

Average tenure and age of the Akero Therapeutics board of directors in years:

1
Average Tenure
52.5
Average Age
  • The average tenure for the Akero Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mark Iwicki

TITLE
Chairman of the Board
COMPENSATION
$74K
AGE
53
TENURE
1 yrs

Andrew Cheng

TITLE
President
COMPENSATION
$1M
AGE
52

Jane Pritchett Henderson

TITLE
Independent Director
AGE
53
TENURE
1 yrs

Kevin Bitterman

TITLE
Independent Director
AGE
43
TENURE
1.8 yrs

Graham Walmsley

TITLE
Independent Director
AGE
32
TENURE
1.8 yrs

Seth Harrison

TITLE
Independent Director
AGE
59
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Mar 20 Sell venBio LLC Company 04. Mar 20 06. Mar 20 -45,950 €21.03 €-963,999
03. Mar 20 Sell venBio LLC Company 28. Feb 20 03. Mar 20 -21,798 €20.68 €-442,351
27. Feb 20 Sell venBio LLC Company 25. Feb 20 27. Feb 20 -5,904 €21.57 €-122,666
12. Feb 20 Sell venBio LLC Company 12. Feb 20 12. Feb 20 -6 €24.91 €-149
12. Feb 20 Sell venBio LLC Company 10. Feb 20 11. Feb 20 -10,020 €24.80 €-248,398
10. Feb 20 Sell venBio LLC Company 06. Feb 20 06. Feb 20 -6,102 €24.61 €-150,191
06. Feb 20 Sell venBio LLC Company 04. Feb 20 05. Feb 20 -82,339 €23.62 €-1,928,225
14. Jan 20 Sell venBio LLC Company 13. Jan 20 13. Jan 20 -494,000 €18.15 €-8,968,275
10. Jan 20 Sell venBio LLC Company 08. Jan 20 08. Jan 20 -15,677 €17.87 €-280,188
08. Jan 20 Sell venBio LLC Company 06. Jan 20 07. Jan 20 -73,221 €18.11 €-1,305,877
06. Jan 20 Sell venBio LLC Company 02. Jan 20 03. Jan 20 -35,498 €17.84 €-626,250
03. Jan 20 Sell venBio LLC Company 31. Dec 19 31. Dec 19 -14,324 €21.35 €-305,878
25. Jun 19 Buy Atlas Venture L.P. Company 24. Jun 19 24. Jun 19 270,000 €14.04 €3,789,504
25. Jun 19 Buy Versant Venture Management, LLC Company 24. Jun 19 24. Jun 19 400,000 €14.04 €5,614,080
25. Jun 19 Buy Apple Tree Partners Company 24. Jun 19 24. Jun 19 900,000 €14.04 €12,631,680
25. Jun 19 Buy venBio LLC Company 24. Jun 19 24. Jun 19 250,000 €14.04 €3,508,800
X
Management checks
We assess Akero Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Akero Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Details
Name: Akero Therapeutics, Inc.
0K4
Exchange: DB
Founded: 2017
$550,462,781
28,558,653
Website: http://www.akerotx.com
Address: Akero Therapeutics, Inc.
170 Harbor Way,
3rd Floor,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AKRO Common Stock Nasdaq Global Select US USD 20. Jun 2019
DB 0K4 Common Stock Deutsche Boerse AG DE EUR 20. Jun 2019
Number of employees
Current staff
Staff numbers
10
Akero Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:20
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/08
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.